Wild Type

UNDERSTANDING wtATTR-CM

WHAT IS wtATTR-CM?

wtATTR-CM is a type of amyloidosis that is thought to be due to age-related changes in the stability of TTR proteins. wtATTR-CM is idiopathic and is not considered to be a hereditary disease. wtATTR-CM is most common in older adults, and the average age of diagnosis is >60 years.^1-5

wtATTR IS THOUGHT TO ACCOUNT FOR THE MAJORITY OF ATTR-CM CASES⁶

PATIENT CONSIDERATIONS

Predominantly affects older, Caucasian men^3,5-7
Symptom onset typically over the age of 60 years⁵

Common characteristics that may present in wtATTR-CM patients:

Heart failure^3,6,7
Cardiac arrhythmias, particularly atrial fibrillation^3,6-8
History of orthopedic manifestations, such as bilateral carpal tunnel syndrome, lumbar spinal stenosis, and/or biceps tendon rupture^9-11

PROGNOSIS

Once diagnosed, untreated patients have a median survival of ~3.5 years.^3,7,12

wtATTR-CM IS AN UNDERDIAGNOSED CAUSE OF HEART FAILURE

PARTICULARLY HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFpEF)^13,14

In 2 studies, wtATTR deposits were identified in the hearts of 10% to 13% of older patients with HFpEF, respectively^13,14:

In a US study of 108 patients referred to a dedicated center, ~10% had ATTR-CM confirmed by endomyocardial biopsy (EMB)¹³*
In an ex-US study conducted in 120 HFpEF patients 60 years or older, wtATTR was confirmed in 13% (13.3%; 95% CI: 7.2-19.5) of the patients^14†

*A prospective analysis in 108 patients (61% women, age range: 57-74 years) seen at the Johns Hopkins University HFpEF Clinic who underwent endomyocardial biopsy to evaluate myocardial tissue histopathology.¹³

^†A prospective, cross-sectional, single-center study at a tertiary university hospital in Madrid, Spain. Included 120 patients ≥60 years of age (59% women, mean age: 82 ± 8 years) admitted for HFpEF, with LV ejection fraction ≥50% and LV hypertrophy ≥12 mm. ^99mtechnetium-labeled 3,3-diphosphono-1,2-propanodicarboxylic acid (^99mTc-DPD) scintigraphy used to confirm ATTR-CM.¹⁴

wtATTR, wild-type transthyretin amyloid fibril protein.

wtATTR-CM estimATTR: A TOOL DESIGNED TO EDUCATE ABOUT CLINICAL CONDITIONS COMMONLY ASSOCIATED WITH wtATTR-CM

A PROBABILITY ESTIMATOR FOR wtATTR-CM

This tool is only to be used by US health care professionals. It is for educational purposes only, and it is not to be used for the suspicion or diagnosis of wtATTR-CM in individual patients in a clinical setting.

estimATTR desktop and responsive layout

TRY IT NOW

The wtATTR-CM estimATTR was developed based on an artificial intelligence/machine learning (AI/ML) algorithm using diagnosis codes from a large, real-world claims dataset comprising more than 1500 patients with wtATTR-CM.

Using hypothetical patient cases presenting with heart failure, the estimATTR can highlight the types of combinations of cardiac and noncardiac conditions that should raise suspicion for wtATTR-CM by:

Estimating the probability of wtATTR-CM based on combinations of clinical features known to be associated with the disease
Illustrating important features that help distinguish between wtATTR-CM and heart failure from other causes

Next section

Suspect the clues of ATTR-CM